Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.

Scientists at the Georgia Institute of Technology have used a new approach, known as RNA-Seq, to profile the gene expression of the bacterium that causes anthrax, Bacillus anthracis.

Two rival biotech companies have been simultaneously awarded governmental contract to develop anthrax vaccine, which needs to be more effective and safe than the existing one. The two companies are Emergent and PharmAthene

Researchers in New Jersey report discovery of a fast, efficient method for removing a powerful pesticide used to sterilize buildings and equipment following anthrax attacks.

Researchers from the National Institute of Standards and Technology (NIST) and the U.S. Army Dugway (Utah) Proving Ground have developed reliable methods based on DNA analysis to assess the concentration and viability of anthrax spores after prolonged storage. The techniques and data are essential steps in developing a reliable reference standard for anthrax detection and decontamination.

Scientists have identified a chemical that could be used as a new drug against anthrax.